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Abstract
Background: Few studies have examined the variation in
oestradiol with respect to age and circadian rhythm and
the subsequent effects on BMD.
Aim: Demonstrate the presence or absence of a circadian
rhythm for oestrodial in older men and the integral role of
concerted circadian rhythms of several factors including
parathyroid hormone (PTH) in regulating biochemical
markers of bone resorption and formation. Examine
whether concentrations of both circulating total and
bioavailable oestrogen in men differ with age and BMD.
Design: Males were recruited: young men with normal
BMD, older men with normal BMD and older men with
osteoporosis.
Methods: Subjects were hospitalized for a 25-hour period.
Blood samples were obtained every 30 minutes. Hormone
analysis results were plotted and reviewed.
Results: Both total and bioavailable oestradiol
concentrations were significantly lower in the older men
than the young men (Total oestradiol: 34.5±4.4 pmol/L vs.
49.0±6.5 pmol/L, p<0.0001; Bioavailable oestradiol
16.7±2.2 pmol/L vs. 26.3±3.6 pmol/L, p<0.0001).
Bioavailable oestrogen rhythm mirrored that of total
estrogen.
Conclusion: Both age groups with normal BMD display
circadian rhythmicity with respect to circulating and
bioavailable oestradiol. Younger men have increased
mean total and bioavailable oestrogen concentrations and
later acrophase compared to older counterparts. In older
men with low BMD, total circulating oestrogen was not
significantly different compared to age-matched older
men with normal BMD; bioavailable oestrogen was
significantly lower. Total oestrogen demonstrated a
concerted circadian rhythm in all 3 groups, but
bioavailable oestrogen did not demonstrate circadian
rhythmicity in older men with decreased BMD.
Introduction
Circulating free and total oestradiol concentrations correlate
with bone mineral density (BMD) in men [1-5]. Oestradiol has
been shown to regulate both bone formation and resorption in
normal elderly men [1]. Circulating total oestradiol decreases
with age in men [1,2] and is associated with increased
circulating osteoprotegerin concentrations. Treatment with
low dose oestrogen has been shown to decrease markers of
bone resorption in elderly men [1].
We have recently demonstrated a circadian rhythm for
osteoprotegerin in older men1 and the integral role of
concerted circadian rhythms of several factors including
parathyroid hormone (PTH) in regulating biochemical markers
of bone resorption and formation which also demonstrate
circadian rhythms is established [1,2].
It has been reported that circulating total oestradiol
demonstrates a diurnal rhythm in men [1,2] but not by others
[3,4]. There have also been conflicting reports with some
studies demonstrating a morning peak as of Bodenheimer [1]
and others demonstrating a late afternoon peak of oestradiol
of Juneja. The circadian rhythm of oestradiol may be a
contributory factor to bone metabolism in men over and
above absolute concentrations.
About 20% of oestrogen in men is produced in the testes [1]
and the remainder is either derived from the peripheral
aromatisation of testosterone (around 60%) or by the
reversible conversion of circulating oestrone (20%) [2].
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Oestradiol circulates in the blood in one of three forms:
bound to sex hormone binding globulin (SHBG) (37%); bound
to albumin (61%); and a small percentage is unbound or free
(2-3%) [1]. The albumin bound fraction of oestradiol is bound
with low affinity and easily dissociated. This albumin bound
oestradiol together with the free fraction is considered to be
biologically active: it can potentially cross the cell membrane,
and is termed bioavailable [1].
Free or bioavailable oestradiol has previously been
calculated using total oestradiol and SHBG concentrations and
an assumed association constant for albumin and SHBG in a
validated algorithm [1-3] or by adapting the method described
for measuring non-SHBG-bound testosterone first described by
Tremblay and Dube. This adaptation has been validated as a
satisfactory estimate of non-SHBG-bound estradiol [1].
To help explain the link between oestrogen and bone
metabolism in men we investigated the differences in
circulating concentrations as well as circadian rhythms of total
and bioavailable oestradiol in young healthy control men with
normal bone mineral density (BMD), older men with normal
BMD and older men with low BMD.
Subjects and Methods
Subjects
Healthy subjects were recruited from hospital personnel and
a database of volunteers willing to participate in medical
research. Subjects with low BMD had been identified in a
community osteoporosis screening program. Nineteen
subjects were recruited for the study; six young healthy men
with normal BMD, eight older men with normal BMD and five
older men with osteoporosis.
All volunteers had BMD measured by dual X-ray
Absorptiometry (DXA) using a Prodigy Oracle Fan-Beam bone
densitometer (GE Medical Systems, Wisconsin, USA). T-scores
were calculated against a reference population of UK subjects
20-39 years of age. All subjects had circulating total
testosterone concentrations in the reference range. Subjects
with diabetes, ischaemic heart disease, heart failure, renal
disease, cancer, chronic illness, vertebral fracture or any
disease or medication such as corticosteroids, affecting the
skeleton were excluded.
Subjects were excluded if they were on calcium and vitamin
D supplements or had previous exposure to bisphosphonate
therapy. Body weight and body mass index were well matched
in all three groups. Baseline characteristics and T-scores are
listed in (Table 1). The local ethics research committee
approved the study, and all patients provided written informed
consent before recruitment.
Table 1: Demographic characteristics of the three groups [Mean ±SEM].
Healthy young men Elderly men with normal BMD Elderly men with osteoporosis
Age years 27.3±4.6 70.5±2.1 75.0±2.9







IGF 1 ug/L 160±42 112±24 72±13
CTX ug/L 0.59±0.22 0.34±0.22 0.69±0.20
P1NP ug/L 83±37 µg/L 44±19 60±13
Testosterone nmol/L 22.2±3.0 15.1±4.0 20.1±8.3
SHBG nmol/L 10.5±4.9 12.8±4.7 24.6±8.4
24 hour total oestradiol pmol/L 49.0±6.5 36.8±3.9 34.5±4.4
Bioavailable oestradiol pmol/L 26.3±3.6 16.7±2.2 12.5±1.8
BMI: body mass index; IGF1 - insulin like growth factor 1;
CTX: type I collagen C-telopeptides;
P1NP : amino-terminal procollagen propeptide 1
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Subjects
Volunteers were hospitalized at 1300 h for a 25 hour period.
Blood samples were obtained every 30 minutes from 1400 -
1400 hr via an indwelling venous cannula inserted in the
antecubital fossa at the time of admission. Each time 7 mL
blood was collected and the samples were immediately
centrifuged, and the plasma was aliquoted and stored at -80°C
before analysis. Subjects remained recumbent during
2300-0800 h and slept during this period. Each patient was
served preset standardized plated hospital meals at 0800,
1200 hours and 1800 hours. The serving sizes and
combinations of foods contained recommended daily
allowances of all nutrients including calcium and phosphate.
Patients were provided with one and a half litres of water and
encouraged to drink at fairly frequent intervals to maintain
hydration. Urine samples were collected at 3-hourly intervals
between 1400-2300 h, overnight from 2300-0800 h and 3-
hourly from 0800-1400 h with a 24 hour urine volume
estimation to assess fluid balance. No significant variability
was observed in the hydration of individuals.
Biochemical Measurements
Total oestradiol was measured by radioimmunoassay using
the Diagnostic Products (DPC) double antibody sensitive
oestradiol kit method (Diagnostic Products Ltd, Llanberris,
North Wales). Each subject’s samples were assayed in the
same batch. Intra-assay and between assay variation was 6%
and 9% at 20 pmol/L and 7% and 9% at 70 pmol/L respectively.
Bioavailable oestradiol was measured using minor
modifications of the Trembley and Dube assay [1]. Briefly,
serum is stripped of steroids using activated charcoal before
incubation at 37 degree centigrade with [3] H-labelled
oestradiol. SHBG is precipitated from the serum using
saturated ammonium sulphate, and the percentage free and
albumin bound oestradiol was determined from the
radioactivity in the supernatant. The concentration of
bioavailable oestradiol was then calculated from the total
oestradiol. Intra-assay and between assay precision was 5%
and 4% at 10 pmol/L and 3% and 3.5% at 50 pmol/L
respectively.
To test the precipitation technique and ensure that all the
SHBG was precipitated by the ammonium sulphate, SHBG
concentrations were assayed in the supernatant after the
addition of saturated ammonium sulphate to the serum. The
10 samples used had SHBG concentrations ranging between
16–106 nmol/L, with one sample from a pregnant woman
whose SHBG concentration was >200 nmol/L. SHBG was
undetectable in all the supernatant from all of the sera used,
indicating that the ammonium sulphate precipitates all the
SHBG.
In our laboratory between-assay precision has been
established at 7.1% at 22.7 pmol/L and 8.6% at 81 pmol/L.
Comparing our measured results with calculated values by
Deming regression analysis revealed an equation of y =1.4x +
3.89 with r2 =1.00. As bioavailable oestradiol is the biologically
active component, measurements using direct assay
techniques may better reflect the role of estrogens in
metabolism.
Statistical Analysis
Individual and population mean cosinor analysis was used
first to confirm circadian rhythmicity and determine the
circadian rhythm variables of total oestradiol and bioavailable
oestradiol using CHRONOLAB 3.0 (Universdade de Vigo, Vigo,
Spain), a software package for analyzing biological time series
by least squares estimation. The software thus provides the
following circadian rhythm variables: 1) midline estimate
statistic of rhythm (MESOR), defined as the rhythm-adjusted
mean or the average value of the rhythmic function fitted to
the data; 2) amplitude, defined as half the extent of rhythmic
change in a cycle approximated by the fitted cosine curve
(difference between the maximum and MESOR of the fitted
curve); and 3) acrophase, defined as the lag between a defined
reference time (1400 h of the first day in our study when the
fitted period is 24 h) and time of peak value of the crest time
in the cosine curve fitted to the data. A p value for the
rejection of the zero-amplitude (no rhythm) assumption is also
determined for each individual series and for the group. The
method used by the program allows analysis of hybrid data
(time series sampled from a group of subjects, each
represented by an individual series). Given k individual series,
the program fits the same linear model with m different
frequencies (harmonics or not from one fundamental period)
to each series. This fit provides estimations for 2m + 1
parameters, namely, the amplitude and acrophase of each
component, as well as the rhythm-adjusted mean. The
population parameter estimates are based on the means of
estimates obtained from individuals in the sample. The
confidence intervals depend on the variability among
individual parameter estimates. The variance-covariance
matrix is then estimated on the basis of the sample
covariances. Confidence intervals for the rhythm-adjusted
mean, as well as for the amplitude-acrophase pair, of each
component is then computed using the estimated covariance
matrix. The p-values for testing the zero-amplitude assumption
for each component, as well as for the global model, are finally
derived using those confidence intervals and the t and F
distributions. Bingham’s test, developed for testing cosinor
parameters and part of CHRONOLAB 3.0 software, was used to
determine the significance of the differences of cosinor-
derived circadian rhythm parameters between subjects.
The differences between groups were determined using
ANOVA for repeated measures taking into account the 49
measurements for each individual in all 3 groups. This method
has been previously validated for similar comparisons.
Repeated measures ANOVA assumes normally distributed
errors, equal variances and sphericity. The Kolmogorov-
Smirnov test was used to confirm normal distribution and
Levenes’s test for equality of variances. Mauchly’s test
indicated that the sphericity assumption was violated and
degrees of freedom were corrected using Greenhouse-Geisser
estimates of sphericity (ε=0.62). The between-group
comparisons of circadian parameters however was performed
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with a single value per individual in each group, using students
t-test for unpaired data. This comparison is subject to type 2
error given the limited number of individuals in the study and
the values of circadian parameters presented in (Table 2) are
MESOR, amplitude and acrophase from the population mean
cosinor analysis (CHRONOLAB 3) for the analytes in all 3
groups. Values are expressed as the mean  SEM. p<0.05 was
considered significant.










Healthy young men (HYM group)
HYM1 16.2±0.6 4.1±0.9 12:25 <0.001*
HYM2 13.7±0.3 1.8±0.4 14:43 <0.001*
HYM3 41.4±0.7 7.0±0.9 11:07 <0.001*
HYM4 28.8±0.7 6.6±0.9 10:07 <0.001*
HYM5 29.3±0.78 3.0±1.1 00:55 0.029*
HYM6 21.4±0.6 5.6±0.8 12:41 <0.001*
Elderly men with Normal BMD (NBMD)
NBMD1 20.2±1.0 2.8±1.4 7:36 0.157
NMBD2 5.7±0.4 1.4±0.5 6:15 0.038*
NBMD3 19.2±0.4 2.0±0.5 8:00 <0.001*
NBMD4 36.4±0.8 6.5±1.2 5:08 <0.001*
NBMD5 15.1±0.7 1.5±0.9 9:50 0.275
NBMD6 20.0±0.3 5.4±0.5 8:43 <0.001*
NBMD7 8.7±0.3 1.630.4 9:24 <0.001*
NBMD8 13.8±0.5 1.9±0.7 11:15 0.023*
Elderly men with Osteoporosis (OBMD)
OBMD1 14.7±0.6 0.9±0.8 6:48 0.583
OBMD2 13.7±0.3 0.6±0.5 5:31 0.467
OBMD3 6.4±0.2 0.3±0.3 12:48 0.484
OBMD4 15.7±0.4 1.3±0.6 11:31 0.100










Healthy young men (HYM)
HYM1 30.3±0.9 6.0±1.3 14:48 <0.001*
HYM2 32.9±0.7 4.3±1.0 13:48 <0.001*
HYM 3 76.5±1.1 14.0±1.5 11:36 <0.001*
HYM4 61.4±1.4 15.8±2.0 9:51 <0.001*
HYM5 54.2±1.38 3.4±1.9 11:27 0.233*
HYM6 31.6±0.9 9,0±1.2 14:55 <0.001*
Older men with normal BMD (NBMD)
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NBMD1 21.4±0.6 3.4±0.8 9:40 <0.001*
NBMD2 40.3±1.6 4.4±2.3 8:40 0.178
NBMD3 31.3±0.8 4.9±1.2 12:03 <0.001*
NBMD4 36.8±0.6 8.7±0.9 10:40 <0.001*
NBMD5 77.6±1.3 14.5±1.8 8:40 <0.001*
NBMD6 28.1±1.0 3.4±1.4 10:15 0.053
NBMD7 10.0±0.8 1.7±1.1 13:43 0.275
NBMD8 36.6±0.7 4.8±1.0 8:31 <0.001*
Older men with Osteoporosis (OBMD)
OBMD1 44.8±1.0 3.1±1.5 10:40 0.107
OBMD2 29.6±0.9 2.5±1.3 10:24 0.166
OBMD3 27.1±0.4 2.5±0.6 13:36 <0.001*
OBMD4 49.9±1.0 7.2±1.4 10:12 <0.001*
OBMD5 32.6±0.8 1.8±1.1 15:58 0.226
Results
Young healthy men vs. older men with normal
BMD
24 h mean concentrations: Both total and bioavailable
oestradiol concentrations were significantly lower in the older
men than the young men (Total oestradiol: 34.5±4.4 pmol/L vs.
49.0±6.5 pmol/L, p<0.0001; Bioavailable oestradiol 16.7± 2.2
pmol/L vs. 26.3±3.6 pmol/L, p<0.0001).
Circadian rhythm: Both total and bioavailable oestradiol
demonstrated concerted circadian rhythmicity with a morning
peak and night time nadir in all the young men and the older
men with normal BMD (Figure 1).
Bioavailable oestrogen rhythm mirrored that of total
estrogen. The group mean MESOR for total oestrogen for the
young men was 47.8±7.8 pmol/L with an amplitude of 7.2±2.7
pmol/L and acrophase at 11:27 am.
The group mean MESOR for bioavailable oestrogen for the
young men was 23.6±4.1 pmol/L with an amplitude of 4.2±1.0
pmol/L and acrophase at 11:15 am. The group mean MESOR
for total oestrogen for the older men with normal BMD was
35.3±7.0 pmol/L with an amplitude of 5.1±1.5 pmol/L and
acrophase at 8:31 am.
The group mean MESOR for bioavailable oestrogen for the
older men with normal BMD was 16.8±3.4 pmol/L with an
amplitude of 2.3±0.6 and acrophase at 7:40 am. The
rhythmometric parameters for the individuals are listed in
(Table 2). The MESORs for both total oestrogen and
bioavailable oestrogen were significantly higher in the young
men when compared with the older men with normal BMD
(p<0.001).
Figure 1: Rhythmometric analysis of bioavailable oestradiol
circadian rhythm in young men compared with older men
with normal BMD.
normal straight line - healthy young men (HYM group)
bold straight line -elderly men with normal BMD ( NBMD
group)
dotted line -osteoporotic elderly men (OBMD group)
With respect to IGF1, the group means MESOR for young
healthy men was 160 ±42 mcg/L; older men with normal bone
density had a group mean MESOR of 112±24 mcg/L. The older
men with reduced BMD had a group mean MESOR of 72±13
mcg/L. CTX and PINP analysis showed that younger men and
elderly men with reduced BMD had higher group mean
MESORs than older men with normal BMD CTX 0.59±0.22
mcg/L and PINP 83±37 mcg/L for younger men compared to
(CTX 0.69±0.2 mcg/L and PINP 60±13 mcg/L for older men
Journal of Clinical and Molecular Endocrinology
Vol.1.No.3: 20
2016
© Under License of Creative Commons Attribution 3.0 License 5
with reduced BMD and CTX 0.34±0.22 mcg/L and PINP 44±19
mcg/L for older men with normal BMD.
Testosterone results showed a pattern consistent with this;
group mean MESOR 22.2±3.0 mcg/L for younger men,
20.1±9.3 mcg/L for older men with reduced BMD and 15.1±4.0
mcg/L for older men with normal BMD. This is reflected in the
SHBG results - group mean MESOR 10.5±4.9 mcg/L for younger
men, 24.6±8.4 mcg/L for older men with reduced BMD and
12.8±4.0 mcg/L for older men with normal BMD.
Older men with normal BMD versus
older men with low BMD
Older men with a reduced BMD had a higher mean
testosterone and SHBG result compared to those with normal
bone density. Their PINP and CTX levels were also significantly
higher than that of counterparts with normal bone density,
with levels similar to those of younger men.
IGF-1 levels were significantly greater in older men with
normal bone density (group mean MESOR 112±24 mcg/L
compared to those with reduced bone density 72±13 mcg/L.
Higher SHBG levels indicate that not all the testosterone
present in the serum is available for bone mineralisation thus
inferring a lower free testosterone level which may result in
lower BMD (Figure 2).
Figure 2: Rhythmometric analysis of bioavailable oestradiol
circadian rhythm in older men with normal BMD compared
with older men with low BMD.
normal straight line - healthy young men (HYM group)
bold straight line -elderly men with normal BMD ( NBMD
group)
dotted line -osteoporotic elderly men (OBMD group)
Figure 3: Rhythmometric analysis of total oestradiol
circadian rhythm in young men compared with older men
with normal BMD.
normal straight line - healthy young men (HYM group)
bold straight line -elderly men with normal BMD ( NBMD
group)
dotted line -osteoporotic elderly men (OBMD group)
Figure 4: Rhythmometric analysis of total oestradiol
circadian rhythm in older men with normal BMD compared
with older men with reduced BMD.
normal straight line - healthy young men (HYM group)
bold straight line -elderly men with normal BMD ( NBMD
group)
dotted line -osteoporotic elderly men (OBMD group)
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24 h mean concentrations
24h mean total oestradiol was similar in both groups of
older men (36.8±3.9 pmol/L for normal BMD subjects vs.
34.5±4.4pmol/L, for low BMD - p<0.0001) but the circulating
bioavailable oestradiol concentration was significantly lower in
the older men with low BMD (12.5±1.8 pmol/L) when
compared with the men with normal BMD (16.7±2.2 pmol/L;
p<0.0001) (Figures 3 and 4).
Discussion
Our findings demonstrate that concentrations of both
circulating total and bioavailable oestrogen in men differ with
age. Whilst both age groups with normal BMD display
circadian rhythmicity with respect to circulating and
bioavailable oestradiol, younger men have higher mean total
and bioavailable oestrogen concentrations compared to older
counterparts. Younger men have a later acrophase compared
to older subjects. In older men with low BMD, total circulating
oestrogen was not significantly different when compared to
age-matched older men with normal BMD, but bioavailable
oestrogen was significantly lower. Total oestrogen
demonstrated a concerted circadian rhythm in all 3 groups, but
bioavailable oestrogen did not demonstrate circadian
rhythmicity in older men with decreased BMD. Concentrations
of IGF-1 were higher in younger men compared with older
counterparts, more so between the young healthy group
(160±42 mcg/L) and the elderly group with decreased BMD
(72± 13 mcg/L). This suggests that the IGF-1 axis may
contribute towards the maintenance of BMD as patients with
higher levels of BMD have a higher level of IGF-1, inferring that
somatotrophin levels rise with BMD. The mean concentrations
of CTX although lower were not statistically different between
younger men and the older group with reduced BMD (0.59
mcg/L vs. 0.69 mcg/L). The mean CTX for older men with
normal BMD was 0.34 mcg/L. PINP results follow a different
pattern with mean concentrations of 83 mcg/L for younger
men, 60 mcg/L for older men with reduced BMD and 44 mcg/L
for older men with normal bone density. This indicates that
overall bone remodeling rates are highest in younger men and
lowest in older men with normal BMD and that “uncoupling” is
present in men with decreased BMD with the highest rate of
bone resorption and the lowest rate of bone formation. The
combination of the difference in resorption and formation
markers suggests a role for regulating hormones acting on the
osteoclast and osteoblast.
The regulation of bone metabolism and maintenance of
BMD in men is complex. The GH and IGF-1 axis [5-7], PTH5-7
and testosterone [5,7] have been shown to contribute. Even
though androgens are the major sex steroids in men, their
predominance in regulating male skeletal remodelling has
been questioned as there is evidence to suggest that
circulating oestrogen has a role in regulating bone mineral
metabolism and bone density in men [1-6]. Evidence to
support the role of oestrogen comes in part from studies in
adult men, rendered temporarily hypogonadal and then
administered aromatase inhibitors. The increase in bone
resorption markers after induction of the hypogonadal state
was almost completely prevented by oestradiol, but not by
testosterone therapy alone, indicating that the increase in
bone resorption was due primarily to oestrogen, not
testosterone loss. It has also been suggested that a threshold
level of bioavailable oestradiol is needed to prevent bone loss,
and that with ageing, a percentage of elderly men begin to fall
below this level. Aromatase activity and hence circulating
estrogen can differ as a result of polymorphisms at the human
aromatase (CYP19) gene, as well as tissue dependent
modulation of aromatase; it is worth considering whether
aromatase activity differs with bone density as older men with
lower BMD have higher testosterone levels but similar total
and bioavailable oestradiol levels to subjects of normal BMD of
the same age [5-12]. Some subjects have almost no circulating
oestrogen due to the polymorphism inherited and require
transdermal oestrogen therapy in order to maintain age-
appropriate skeletal development, bone density and
spermatogenesis. These differences become more pronounced
in older men [5] and may account for the difference in
bioavailable oestrogen observed in the 2 groups of older men
in our study. Our observation of the lower bioavailable
oestrogen concentration in the men with low BMD also
supports the role of oestrogen in maintaining bone density in
men. Recent population based studies [6-24] have also
suggested that SHBG may also be an independent predictor for
bone loss in men. Our finding of the presence of a lower
bioavailable oestradiol concentration in the presence of similar
total oestradiol concentrations in the men with low BMD when
compared with the men with normal BMD would be in keeping
with the previously demonstrated association of a raised SHBG
and low BMD. It is likely however that a higher SHBG results in
a lower availability of biologically active oestrogen resulting in
a lack of maintenance of bone mineral metabolism and BMD.
The morning peak and nocturnal nadir in total and
bioavailable oestrogen in the young healthy men and older
men with normal BMD is in keeping with previous reports of
Bodenheimer and Carlsen [1]. The absence of a concerted
circadian rhythm in bioavailable oestrogen in the older men
with low BMD suggests that as with other endocrine regulators
of bone metabolism, rhythmicity of bioavailable oestrogen
may be important, over and above circulating concentrations
alone. When compared with the previously reported rhythm
of circulating testosterone [25], both total and bioavailable
oestradiol rhythms lag behind those of testosterone by
approximately 2-4 hours possibly reflecting the peripheral
conversion of testosterone to oestrogen, which is the
predominant source of circulating oestrogen in men.
It has previously been shown that markers of bone
resorption demonstrate an entrained circadian rhythmicity
with a nocturnal peak in both men and women. Alterations in
this rhythmicity have been studied in more detail in
postmenopausal women who are oestrogen deficient and may
be mediated at least in part by altered PTH and
osteoprotegerin rhythms. The circadian rhythm of oestrogen
we observed in the young men and the older men with normal
BMD appear to be opposite to the previously described
rhythm of bone resorption markers. It is possible that the
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higher nocturnal concentrations of resorption markers may be
a result of the lack of oestrogen restraint on osteoclasts.
Future studies would require the assessment of bone turnover
markers and oestrogen in older men with low BMD, most
particularly the effects of oestradiol on altering PTH
responsiveness and the dual variables of a modified/deficient
PTH rhythm with altered circulating oestradiol rhythms in
order to enhance our understanding.
We believe our findings support a significant role for
circulating oestrogen in regulating bone turnover in men. Our
study demonstrates that concentrations of both circulating
total and bioavailable oestrogen in men differ with age. Whilst
both age groups with normal BMD display circadian
rhythmicity with respect to circulating and bioavailable
oestradiol, younger men have increased mean total and
bioavailable oestrogen concentrations compared to older
counterparts. Younger men have a later acrophase compared
to older subjects. In older men with low BMD, total circulating
oestrogen was not significantly different when compared to
age-matched older men with normal BMD, but bioavailable
oestrogen was significantly lower. Total oestrogen
demonstrated a concerted circadian rhythm in all 3 groups, but
bioavailable oestrogen did not demonstrate circadian
rhythmicity in older men with decreased BMD. IGF-1 levels
appear to the a significant factor in the maintainance of bone
density across age groups, with reduced BMD subjects
demonstrating lower levels than those with normal BMD. In
conclusion, our study adds a further piece of information to
understanding the complex pathophysiology of the
development of osteoporosis in men.
Reference
1. Slemenda CW (1997) Sex steroids and bone mass in older
men: positive associations with serum estrogens and
negative associations with androgens. J Clin Invest 100:
1755-1759.
2. Greendale GA, Edelstein S, Barrett-Connor E (1997)
Endogenous sex steroids and bone mineral density in
older women and men: the Rancho Bernardo Study. J
Bone Miner Res 12: 1833-1843.
3. Khosla S, Melton LJ, Atkinson EJ, O'Fallon WM, Klee GG, et
al. (1998) Relationship of serum sex steroid levels and
bone turnover markers with bone mineral density in men
and women: a key role for bioavailable estrogen. J Clin
Endocrinol Metab 83: 2266-2274.
4. Ongphiphadhanakul B (1998) Serum oestradiol and
oestrogen-receptor gene polymorphism are associated
with bone mineral density independently of serum
testosterone in normal males. Clin Endocrinol 49:
803-809.
5. Center JR, Nguyen TV, Sambrook PN, Eisman JA (1999)
Hormonal and biochemical parameters in the
determination of osteoporosis in elderly men. J Clin
Endocrinol Metab 84: 3626-3635.
6. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM,
Eastell R, et al. (2000) Relative contributions of
testosterone and estrogen in regulating bone resorption
and formation in normal elderly men. J Clin Invest 106:
1553-1560.
7. Riggs BL, Khosla S, Melton LJ (1998) A unitary model for
involutional osteoporosis: estrogen deficiency causes
both type I and type II osteoporosis in postmenopausal
women and contributes to bone loss in aging men. J Bone
Miner Res 13: 763-773.
8. Szulc P, Munoz F, Claustrat B, Garnero P, Marchand F, et al.
(2001) Bioavailable estradiol may be an important
determinant of osteoporosis in men: the MINOS study. J
Clin Endocrinol Metab 86: 192-199.
9. Taxel P, Raisz LG (1997) The effect of estrogen therapy on
older men with low bone mass. J Bone Miner Res 12:
S353.
10. Joseph F, Chan BY, Durham BH, Ahmad AM, Vinjamuri S,
et al. (2007) The circadian rhythm of osteoprotegerin and
its association with parathyroid hormone secretion. J Clin
Endocrinol Metab 92: 3230-3238.
11. Ahmad AM, Hopkins MT, Fraser WD, Ooi CG, Durham BH,
et al. (2003) Parathyroid hormone secretory pattern,
circulating activity, and effect on bone turnover in adult
growth hormone deficiency. Bone 32: 170-179.
12. Ahmad AM, Thomas J, Clewes A, Hopkins MT, Guzder R,
et al. (2003) Effects of growth hormone replacement on
parathyroid hormone sensitivity and bone mineral
metabolism. J Clin Endocrinol Metab 88: 2860-2868.
13. Carlsen E, Olsson C, Petersen JH, Andersson AM,
Skakkebaek NE (1999) Diurnal rhythm in serum levels of
inhibin B in normal men: relation to testicular steroids
and gonadotropins. J Clin Endocrinol Metab 84:
1664-1669.
14. Juneja HS, Karanth S, Dutt A (1991) Diurnal variations and
temporal coupling of bioactive and immunoactive
luteinizing hormone, prolactin, testosterone and 17-beta-
estradiol in adult men. Horm Res 35: 89-94.
15. Nankin HR, Pinto R, Fan DF (1975) Daytime titers of
testosterone, LH, estrone, estradiol, and testosterone-
binding protein: acute effects of LH and LH-releasing
hormone in men. J Clin Endocrinol Metab 41: 271-281.
16. Murono EP, Nankin HR, Lin T, Osterman J (1982) The aging
Leydig cell V. Diurnal rhythms in aged men. Acta
Endocrinol 99: 619-623.
17. Bodenheimer S, Winter JS, Faiman C (1973) Diurnal
rhythms of serum gonadotropins, testosterone, estradiol
and cortisol in blind men. J Clin Endocrinol Metab 37:
472-475.
18. Sayed Y, Taxel P (2003) The use of estrogen therapy in
men. Curr Opin Pharmacol 3: 650-654.
Journal of Clinical and Molecular Endocrinology
Vol.1.No.3: 20
2016
8 This article is available from: http://clinical-and-molecular-endocrinology.imedpub.com/
19. de Ronde W, Pols HA, van Leeuwen JP, de Jong FH (2003)
The importance of oestrogens in males. Clin Endocrinol
58: 529-542.
20. Pardridge WM (1986) Serum bioavailability of sex steroid
hormones. Clin Endocrinol Metab 15: 259-278.
21. Rinaldi S, Geay A, Dechaud H, Biessy C (2002). Validity of
free testosterone and free estradiol determinations in
serum samples from postmenopausal women by
theoretical calculations. Cancer Epidemiol Biomarkers
Prev 11: 1065-1071.
22. Sodergard R, Backstrom T, Shanbhag V, Carstensen H
(1982) Calculation of free and bound fractions of
testosterone and estradiol-17 beta to human plasma
proteins at body temperature. J Steroid Biochem 16:
801-810.
23. Vermeulen A, Goemaere S, Kaufman JM (1999)
Testosterone, body composition and aging. J Endocrinol
Invest 22: 110-116.
24. Karim R, Hodis HN, Stanczyk FZ, Lobo RA, Mack WJ (2008)
Relationship between serum levels of sex hormones and
progression of subclinical atherosclerosis in
postmenopausal women. J Clin Endocrinol Metab 93:
131-138.
25. Szulc P, Munoz F, Claustrat (2001) Bioavailable estradiol
may be an important determinant of osteoporosis in men.
J Clin Endocrinol Metab 86: 192-199.
 
Journal of Clinical and Molecular Endocrinology
Vol.1.No.3: 20
2016
© Under License of Creative Commons Attribution 3.0 License 9
